IT201900024961A1 - Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension - Google Patents

Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension

Info

Publication number
IT201900024961A1
IT201900024961A1 IT102019000024961A IT201900024961A IT201900024961A1 IT 201900024961 A1 IT201900024961 A1 IT 201900024961A1 IT 102019000024961 A IT102019000024961 A IT 102019000024961A IT 201900024961 A IT201900024961 A IT 201900024961A IT 201900024961 A1 IT201900024961 A1 IT 201900024961A1
Authority
IT
Italy
Prior art keywords
bimatoprost
formulations
treatment
solution
ocular hypertension
Prior art date
Application number
IT102019000024961A
Other languages
Italian (it)
Inventor
Patrizia Chetoni
Susi Burgalassi
Daniela Monti
Silvia Tampucci
Christina Matsigkou
Original Assignee
Rafarm Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rafarm Uk Ltd filed Critical Rafarm Uk Ltd
Priority to IT102019000024961A priority Critical patent/IT201900024961A1/en
Priority to US17/755,492 priority patent/US20220409630A1/en
Priority to CA3156433A priority patent/CA3156433A1/en
Priority to PCT/IB2020/060277 priority patent/WO2021084522A1/en
Priority to AU2020376025A priority patent/AU2020376025A1/en
Priority to EP20808513.4A priority patent/EP4051234A1/en
Publication of IT201900024961A1 publication Critical patent/IT201900024961A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
IT102019000024961A 2019-10-31 2019-12-20 Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension IT201900024961A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IT102019000024961A IT201900024961A1 (en) 2019-12-20 2019-12-20 Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension
US17/755,492 US20220409630A1 (en) 2019-10-31 2020-11-02 Bimatoprost 0.01% solution compositions for the treatment of ocular hypertenstion
CA3156433A CA3156433A1 (en) 2019-10-31 2020-11-02 Bimatoprost 0.01% solution compositions for the treatment of ocular hypertension
PCT/IB2020/060277 WO2021084522A1 (en) 2019-10-31 2020-11-02 Bimatoprost 0.01% solution compositions for the treatment of ocular hypertension
AU2020376025A AU2020376025A1 (en) 2019-10-31 2020-11-02 Bimatoprost 0.01% solution compositions for the treatment of ocular hypertension
EP20808513.4A EP4051234A1 (en) 2019-10-31 2020-11-02 Bimatoprost 0.01% solution compositions for the treatment of ocular hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000024961A IT201900024961A1 (en) 2019-12-20 2019-12-20 Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension

Publications (1)

Publication Number Publication Date
IT201900024961A1 true IT201900024961A1 (en) 2021-06-20

Family

ID=70295615

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000024961A IT201900024961A1 (en) 2019-10-31 2019-12-20 Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension

Country Status (1)

Country Link
IT (1) IT201900024961A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1753434A2 (en) 2005-03-16 2007-02-21 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2014204791A1 (en) * 2013-06-21 2014-12-24 Gnt, Llc Ophthalmic lipophilic and hydrophilic drug delivery vehicle formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1753434A2 (en) 2005-03-16 2007-02-21 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2014204791A1 (en) * 2013-06-21 2014-12-24 Gnt, Llc Ophthalmic lipophilic and hydrophilic drug delivery vehicle formulations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Assessment report for Lumigan", EUROPEAN MEDICINES AGENCY, 7 January 2010 (2010-01-07), pages 31
EDSMAN K.CARLFORS J.: "Rheological evaluation of poloxamer as an in situ gel for ophthalmic use", EUR. J. PHARM. SKIING, vol. 6, 1998, pages 105, XP055420052, DOI: 10.1016/S0928-0987(97)00075-4
GIULIANO E. ET AL.: "mucosal applications of Poloxamer 407-based hydrogen gels: An Overview", PHARMACEUTICS, vol. 10, no. 3, 2018, pages 159
LIHONG W. ET AL.: "Thermopthalmic poloxamer/tween/carbopol in situ gels of a poorly water-soluble drug flu-conazole: preparation and in vitro-in vivo evaluation", DRUG DEV. IND. PHARM., vol. 40, no. 10, 2014, pages 1402 - 1410
MARK GIBSON: "pharmaceutical Preformulation and for-Regulation", 2009, HEALCARE

Similar Documents

Publication Publication Date Title
DOP2020000037A (en) DERIVATIVES OF 3- (1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES THEREOF
EA200700035A1 (en) SULPHATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DI SORDERS
DK3906066T5 (en) GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF WILSON'S DISEASE
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
EA201270480A1 (en) NEW CONNECTIONS
EA200601648A1 (en) GLUCOSAMINE AND GENERAL PROCEDURES GLUCOSAMINE / ANTI-INFLAMMATORY AGENT, COMPOSITIONS AND METHODS
DE602006010738D1 (en) PYRROLOÄ2,3-CÜPYRIDINDERIVATE
MD4047002T2 (en) Antitumoral compounds
MX2021012491A (en) Anti-proliferative agents for treating pah.
EA201992744A1 (en) PHARMACEUTICAL COMPOSITIONS N- (2- (2- (DIMETHYLAMINO) ETOXY) -4-METOXY-5 - ((4- (1-METHYL-1H-INDOL-3-IL) PYRIMIDIN-2-IL) AMINO) Phenyl) Acrylamide AND HIS SALTS
DK1809270T3 (en) 5,6,7-trihydroxyheptanoic acid and analogues for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic reactions
BR112018068960A2 (en) enalapril formulations
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
BR112017012646A2 (en) SOLID FORMS UNDERSTANDING (1E, 4E) -2-AMINO- N, N-DIPROPIL-8- (4- (PIRROLIDIN-1-CARBONYL) PHENYL) -3H- BENZO [B] AZEPINE-4-CARBOXAMIDE, COMPOSITIONS OF THE SAME, AND USE OF THE SAME
CY1109666T1 (en) METHOD OF THERAPEUTIC AND RACOIDIS DISEASE TREATMENT
BR112012017319A2 (en) compositions and methods for lowering intraocular pressure
ATE536101T1 (en) TREATMENT OF DRUG-RESISTANT PROLIFERATIVE DISEASES
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
MX2022005084A (en) Solid forms of an s1p-receptor modulator.
IT201900024961A1 (en) Formulations of bimatoprost in 0.01% solution for the treatment of ocular hypertension
FR3097767B1 (en) Active ingredient obtained from Nymphaea alba flowers
EP3843690A4 (en) Personal care spray compositions and methods comprising trans-1-chloro-3,3,3-trifluoropropene
EA201792170A1 (en) INDOLA DERIVATIVES
EA202190045A1 (en) COMPOSITIONS / COMPOSITIONS CONTAINING IBRUTINIB
PH12020500001A1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions